Thymalin
Also known as: Thymalin-Vilon · Tymalin · Russian thymic complex
Approved in Russia for 30+ years; mild AE profile in clinical use; no Western RCTs; replication outside Khavinson group is limited.
Rating per Panya's data-first method, not regulator endorsement. The mechanism, dose, and risk sections below carry the underlying data.
Thymalin is a Russian peptide preparation derived from thymic extracts, used in the USSR/Russia for immune support, post-surgical recovery, and infection adjuvant. Distinct from Thymosin Alpha-1 (which is a single defined peptide); Thymalin is a complex of low-molecular-weight thymic peptides.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like Thymalin, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any Thymalin vendor.
Not medical advice. Thymalin is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
Thymalin was developed in the USSR in the 1970s by extracting low-molecular-weight peptides from bovine thymus. The Khavinson lab in St Petersburg later characterised specific bioactive components and proposed Thymalin upregulates T-cell maturation in immunocompromised states by restoring thymic-pathway signalling. Mechanistic claims include: increased CD3+ and CD4+ counts in elderly cohorts, normalisation of CD4/CD8 ratio after immune insult, and modulation of cytokine production toward a balanced Th1/Th2 profile. Most published mechanistic and clinical evidence comes from the Khavinson group and Russian-language journals; independent Western replication is limited, which is the central scrutiny point on this peptide. Confused easily with Thymosin Alpha-1 (the single 28-residue peptide isolated from thymic fraction 5); the catalog covers them as separate entries.
Typical practice
Russian clinical practice and community protocols converge on 5 to 10 mg intramuscular or subcutaneous daily, in cycles of 5 to 10 days, repeated 2 to 4 times per year. Some users intranasal at lower doses. Reconstitution is typically a 10 mg vial in 1 to 2 mL bacteriostatic water or saline. The original Russian clinical trials used dose ranges of 5 to 30 mg per cycle depending on indication. There is no Western regulator-validated dosing protocol; the doses above reflect Russian clinical use and community practice. Cycle rationale is theoretical (avoid receptor desensitisation) and not empirically validated outside the Khavinson cohorts.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for Thymalin in humans does not exist for most use cases listed.
Risks and contraindications
Reported side effects in Russian clinical use and community logs are mild: transient injection-site soreness, occasional low-grade fever in the first 24 hours of a cycle (consistent with immune-pathway activation). T-cell-modulating agents have potential to interact with autoimmune disease pathways; no clinical data exists in autoimmune cohorts (lupus, MS, RA). Thymic peptides have been proposed as adjuvants in oncology contexts in the Russian literature; the Western trial evidence is sparse and no clinical safety data exists for active-cancer cohorts. No trial data exists in pregnancy or lactation cohorts. Drug interactions have not been formally characterised. Independent replication of the Khavinson findings outside the originating research group is limited.
Where this stands legally
Not FDA-approved. Sold as a research peptide 'not for human consumption.' Customs scrutiny on personal-import peptides has tightened.
Not on the MHRA approved list. Sale as research peptide is technically lawful; human use is medically unsupervised.
Not approved by EMA. Imported variants from Russian manufacturers occasionally available; quality and provenance vary.
TGA Schedule 4 (prescription-only) for injectable peptides not on the approved list. Personal-use imports actively investigated.
Not approved by Thai FDA. Available through research-peptide vendors and some longevity/integrative-medicine clinics. No formal enforcement against personal use.
HSA classifies injectable peptides without product registration as prescription-controlled. Sold legally only through licensed clinics.
Sold through wellness clinics and research-peptide channels in HCMC and Hanoi. Vietnam Drug Administration enforcement is light on research peptides.
Originating jurisdiction. Approved for clinical use since the late USSR period. Used in Russian gerontology, post-surgical, and infectious-disease settings under physician supervision.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Russian peptide pharmacies (legitimate manufacturers exist in jurisdictions where Thymalin is approved)Pending Panya 11-signal audit
- International research-peptide suppliers with COA per lot (audit the COA, not the marketing)Pending Panya 11-signal audit
- Khavinson-affiliated commercial channels (the original clinical-research provenance)Pending Panya 11-signal audit
Full vendor scorecards for Thymalin land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Khavinson VKh, Morozov VG. (2003) Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett →
- Khavinson VKh. (2002) Peptides and Ageing. Neuroendocrinol Lett (Suppl) →
- Kuznik BI, Khavinson VKh, Linkova NS et al. (2011) Peptide bioregulators and aging: a review of the field. Adv Gerontol →
- Anisimov VN, Khavinson VKh. (2010) Peptide bioregulation of aging: results and prospects. Biogerontology →
Adjacent reading
Track Thymalin in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.